Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Acral lentiginous melanoma

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma